Innate Pharma - IPHA Book Capitalization

The price chart for Innate Pharma S.A. (IPHA) reflects the dynamics of a company developing advanced antibodies to combat tumors through partnerships with industry leaders. The current metric reaches -0.05. The firm benefits from royalties on its patents by transferring rights to major players. However, the business faces stiff price competition and clinical trial uncertainty, necessitating the attraction of external capital.

innate-pharma.com (IPHA) - Company Book Value from 07/04/2022 to 10/27/2026

Comprehensive metric breakdowns and analytics for Innate Pharma (IPHA)

- price and consensus price forecast:

Price Performance Chart Innate Pharma S.A|IPHA - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Innate Pharma SA|IPHA - Total Company Value

- book capitalization data:

Net Asset Value per Share Innate Pharma|IPHA - Company Book Value|Capitalization to Book Value Ratio innate-pharma.com|IPHA - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Innate Pharma S.A.|IPHA - Long-Term Debt to Equity|Current Liabilities to Capital Innate Pharma SA|IPHA - Company Debts|Debt to Book Capitalization Ratio Innate Pharma SA

Initial company analysis:Innate Pharma S.A - IPHA

Flagship merchandise of Innate Pharma S.A.

Book value capitalization serves as a key filter for investment reliability, determining the real value of the issuer's assets. This metric compares the market value of the business with its net asset base to identify share overvaluation. By analyzing changes in book value capitalization, an investor assesses long-term capital stability. For Innate Pharma S.A. (IPHA), this indicator confirms a fundamental base supported by the development of oncology antibodies. Partnerships with industry behemoths ensure asset value during the business maturity phase.

Key competitors